Andere Sprachen Lupin Limited NSE India S.E.

Aktien

A1C4HE

INE326A01037

LUPIN

Markt geschlossen - NSE India S.E. Andere Börsenplätze 13:43:49 07.05.2024			% 5 Tage	% 1. Jan.
1.611 ^INR	-4,11 %		-2,14 %	+21,74 %

06.05.	Indischer Arzneimittelhersteller Lupin verfehlt wegen steigender Kosten die Schätzungen für den Quartalsgewinn	RE
06.05.	Lupin Limited meldet Ergebnis für das vierte Quartal bis zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Lupin's Consolidated Profit Climbs in Fiscal Q4; Shares Dip 4%	06:52
Indian drugmaker Lupin misses quarterly profit estimates as costs rise	06.05.
Lupin : May 6, 2024 Lupin Receives Approval from U.S. FDA for Travoprost Ophthalmic Solution USP	06.05.
Lupin Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	06.05.
Lupin Limited Reports Earnings Results for the Full Year Ended March 31, 2024	06.05.
Lupin : May 3, 2024 Lupin Launches Rymti® Biosimilar Etanercept in Canada	03.05.
Lupin Limited Receives an Order from Office of the State Tax Inspector, Jurisdiction: Ghatak 56: Range - 14: Division - 6: Gujarat	30.04.
Lupin : April 25, 2024 Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Suspension, 0.5%	25.04.
Lupin : April 25, 2024 Lupin Digital Health’s Lyfe Platform Receives Class C Medical Device License from CDSCO	25.04.
Lupin Receives US FDA Inspection Report for Aurangabad, India Manufacturing Facility	24.04.
Lupin : April 23, 2024 Lupin Receives EIR from U.S. FDA for its Aurangabad Manufacturing Facility	24.04.
Lupin : April 22, 2024 Lupin Launches Mirabegron Extended-Release Tablets in the United States	22.04.
INDIA STOCKS-Indian shares rise tracking Asia rebound; drop in HDFC Bank caps gains	22.04.
Lupin Launches Mirabegron Extended-Release Tablets in US	22.04.
Lupin Limited Announces Launch of Mirabegron Extended-Release Tablets, 25 Mg, in the United States, After Having Received an Approval from the United States Food and Drug Administration	20.04.
Lupin : April 12, 2024 U.S. FDA Completes Inspection of Lupin’s Dabhasa Facility with No Observations	12.04.
US FDA Clears Lupin's API Plant in Gujarat, India, Following GMP Inspection	12.04.
Lupin Launches Generic Version of Oracea (Doxycycline Capsules) in US	10.04.
Lupin : April 9, 2024 Lupin Launches First Generic Version of Oracea® (Doxycycline Capsules) in the United States	09.04.
Lupin Launches Generic Drug for Inflammatory Lesions of Rosacea in US	09.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Lupin Limited NSE India S.E.

Aktien

A1C4HE

INE326A01037

LUPIN

Andere Sprachen

Filter